Everest Medicines gibt Termin für außerordentliche Hauptversammlung bekannt

Reuters02-03
Everest Medicines gibt Termin für außerordentliche Hauptversammlung bekannt

Everest Medicines Ltd. hält am 22. Februar 2026 eine außerordentliche Hauptversammlung als virtuelle Sitzung ab. Auf der Tagesordnung stehen unter anderem die Genehmigung fortlaufender verbundener Transaktionen im Zusammenhang mit dem Commercialization Service Agreement, die vorgeschlagene Zuteilung von Aktien an eine verbundene Person, die Beantragung eines Verzichts auf bestimmte Anforderungen sowie die geplante Einführung des 2026 Share Scheme.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011248), on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment